Free Trial

CRISPR Therapeutics (CRSP) Competitors

CRISPR Therapeutics logo
$58.74 -1.34 (-2.23%)
As of 02:55 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

CRSP vs. ALLO, AXSM, BEAM, EDIT, KALA, MRNA, NTLA, VRTX, SMMT, and ITCI

Should you be buying CRISPR Therapeutics stock or one of its competitors? The main competitors of CRISPR Therapeutics include Allogene Therapeutics (ALLO), Axsome Therapeutics (AXSM), Beam Therapeutics (BEAM), Editas Medicine (EDIT), KALA BIO (KALA), Moderna (MRNA), Intellia Therapeutics (NTLA), Vertex Pharmaceuticals (VRTX), Summit Therapeutics (SMMT), and Intra-Cellular Therapies (ITCI). These companies are all part of the "medical" sector.

CRISPR Therapeutics vs. Its Competitors

CRISPR Therapeutics (NASDAQ:CRSP) and Allogene Therapeutics (NASDAQ:ALLO) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, dividends, valuation, earnings, profitability, risk, institutional ownership and media sentiment.

Allogene Therapeutics has a net margin of 0.00% compared to CRISPR Therapeutics' net margin of -1,023.64%. CRISPR Therapeutics' return on equity of -20.08% beat Allogene Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
CRISPR Therapeutics-1,023.64% -20.08% -17.13%
Allogene Therapeutics N/A -52.98%-41.28%

In the previous week, CRISPR Therapeutics had 12 more articles in the media than Allogene Therapeutics. MarketBeat recorded 13 mentions for CRISPR Therapeutics and 1 mentions for Allogene Therapeutics. CRISPR Therapeutics' average media sentiment score of 0.47 beat Allogene Therapeutics' score of 0.00 indicating that CRISPR Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
CRISPR Therapeutics
3 Very Positive mention(s)
2 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Allogene Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Allogene Therapeutics has lower revenue, but higher earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Allogene Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CRISPR Therapeutics$37.31M135.78-$366.25M-$4.52-12.98
Allogene TherapeuticsN/AN/A-$257.59M-$1.23-1.02

CRISPR Therapeutics presently has a consensus target price of $71.75, suggesting a potential upside of 22.31%. Allogene Therapeutics has a consensus target price of $8.44, suggesting a potential upside of 572.86%. Given Allogene Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Allogene Therapeutics is more favorable than CRISPR Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CRISPR Therapeutics
1 Sell rating(s)
6 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.53
Allogene Therapeutics
0 Sell rating(s)
1 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.90

CRISPR Therapeutics has a beta of 1.82, meaning that its stock price is 82% more volatile than the S&P 500. Comparatively, Allogene Therapeutics has a beta of 0.31, meaning that its stock price is 69% less volatile than the S&P 500.

69.2% of CRISPR Therapeutics shares are owned by institutional investors. Comparatively, 83.6% of Allogene Therapeutics shares are owned by institutional investors. 4.3% of CRISPR Therapeutics shares are owned by insiders. Comparatively, 13.2% of Allogene Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Allogene Therapeutics beats CRISPR Therapeutics on 8 of the 15 factors compared between the two stocks.

Get CRISPR Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CRSP and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRSP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CRSP vs. The Competition

MetricCRISPR TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$5.06B$2.97B$5.59B$9.03B
Dividend YieldN/A2.44%5.25%4.03%
P/E Ratio-12.9721.1027.2020.21
Price / Sales135.78259.44416.10175.56
Price / CashN/A41.8337.0657.97
Price / Book2.597.768.085.61
Net Income-$366.25M-$54.96M$3.16B$248.50M
7 Day Performance12.48%5.71%3.70%5.15%
1 Month Performance36.62%4.13%3.85%7.66%
1 Year Performance5.58%5.95%34.01%21.66%

CRISPR Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CRSP
CRISPR Therapeutics
2.4468 of 5 stars
$58.66
-2.4%
$71.75
+22.3%
+9.2%$5.06B$37.31M-12.97460Analyst Forecast
Options Volume
Gap Up
ALLO
Allogene Therapeutics
2.996 of 5 stars
$1.17
-2.1%
$8.44
+624.8%
-47.4%$252.63M$20K-0.94310
AXSM
Axsome Therapeutics
4.7359 of 5 stars
$106.70
+1.2%
$172.33
+61.5%
+38.3%$5.25B$385.69M-18.49380
BEAM
Beam Therapeutics
2.6711 of 5 stars
$19.40
-3.0%
$48.75
+151.3%
-10.0%$1.95B$63.52M-4.20510News Coverage
Gap Up
EDIT
Editas Medicine
4.0586 of 5 stars
$2.58
+0.2%
$4.70
+82.5%
-37.3%$215.55M$32.31M-0.85230
KALA
KALA BIO
3.6828 of 5 stars
$5.26
+3.1%
$13.50
+156.7%
-11.4%$34.09M$3.89M-0.6430News Coverage
Gap Up
MRNA
Moderna
4.4704 of 5 stars
$30.25
-0.8%
$46.61
+54.1%
-71.7%$11.69B$3.24B-3.465,800Gap Up
NTLA
Intellia Therapeutics
4.6484 of 5 stars
$10.47
-2.6%
$33.37
+218.9%
-45.5%$1.08B$57.88M-2.00600
VRTX
Vertex Pharmaceuticals
4.4624 of 5 stars
$459.70
+0.0%
$511.62
+11.3%
-1.4%$117.98B$11.10B-117.206,100Positive News
Analyst Revision
SMMT
Summit Therapeutics
2.4935 of 5 stars
$23.06
-6.1%
$34.67
+50.3%
+215.6%$17.14B$700K-67.90110
ITCI
Intra-Cellular Therapies
0.7424 of 5 stars
$131.87
flat
$109.70
-16.8%
N/A$14.05B$680.50M-151.57560

Related Companies and Tools


This page (NASDAQ:CRSP) was last updated on 7/10/2025 by MarketBeat.com Staff
From Our Partners